search
Back to results

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
liraglutide
placebo
glimepiride
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes
  • Diet and lifestyle changes or metformin monotherapy for at least three months
  • HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive)
  • Body Mass Index (BMI) less than or equal to 40 kg/m^2

Exclusion Criteria:

  • Previous treatment with insulin (except for short term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator)
  • Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including treatment in a clinical trial
  • Treatment with any oral hypoglycaemic agents other than metformin in a period of 3 months prior to screening
  • Current smoker or history of smoking within 6 months prior to screening
  • Evidence of overt cardiovascular disease (documented coronary heart disease, class II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular disease)
  • Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as judged by the Investigator
  • Known retinopathy or maculopathy requiring acute treatment, as judged by the Investigator
  • Known autonomic neuropathy, as judged by the Investigator
  • Initiation or change (dose or treatment regimen) in concomitant blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening
  • Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg

Sites / Locations

  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

Active Comparator

Arm Label

Lira 1.8

Placebo

Glimepiride

Arm Description

Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)

Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)

Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12

Outcomes

Primary Outcome Measures

Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)
Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.

Secondary Outcome Measures

Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)
Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
Change in HbA1c (Glycosylated Haemoglobin A1c)
Percentage point change in HbA1c
Change in Fasting Plasma Glucose (FPG)
Change in FPG
Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles
The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime.
Change in Body Weight
Fasting Lipid Profile - Change in Total Cholesterol (TC)
Change in TC
Fasting Lipid Profile - Change in LDL-C
Change in LDL-C
Fasting Lipid Profile - Change in HDL-C
Change in HDL-C
Fasting Lipid Profile - Change in Triglycerides (TG)
Change in TG
Biomarkers of Cardiovascular Risk - Change in TNF-alpha
Change in TNF-alpha
Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range
Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL).
Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range
Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL).
Number of Hypoglycaemic Episodes
Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.

Full Information

First Posted
February 11, 2008
Last Updated
January 25, 2017
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT00620282
Brief Title
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
Official Title
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
49 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lira 1.8
Arm Type
Experimental
Arm Description
Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
Arm Title
Glimepiride
Arm Type
Active Comparator
Arm Description
Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
Intervention Type
Drug
Intervention Name(s)
liraglutide
Intervention Description
Stepwise dose increase, s.c. (under the skin) injection, once daily
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
Intervention Type
Drug
Intervention Name(s)
glimepiride
Intervention Description
Tablets, 1 - 4 mg daily
Primary Outcome Measure Information:
Title
Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)
Description
Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
Time Frame
week 0, week 12
Secondary Outcome Measure Information:
Title
Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)
Description
Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
Time Frame
week 0, week 12
Title
Change in HbA1c (Glycosylated Haemoglobin A1c)
Description
Percentage point change in HbA1c
Time Frame
week 0, week 12
Title
Change in Fasting Plasma Glucose (FPG)
Description
Change in FPG
Time Frame
week 0, week 12
Title
Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles
Description
The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime.
Time Frame
week 0, week 12
Title
Change in Body Weight
Time Frame
week 0, week 12
Title
Fasting Lipid Profile - Change in Total Cholesterol (TC)
Description
Change in TC
Time Frame
week 0, week 12
Title
Fasting Lipid Profile - Change in LDL-C
Description
Change in LDL-C
Time Frame
week 0, week 12
Title
Fasting Lipid Profile - Change in HDL-C
Description
Change in HDL-C
Time Frame
week 0, week 12
Title
Fasting Lipid Profile - Change in Triglycerides (TG)
Description
Change in TG
Time Frame
week 0, week 12
Title
Biomarkers of Cardiovascular Risk - Change in TNF-alpha
Description
Change in TNF-alpha
Time Frame
week 0, week 12
Title
Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range
Description
Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL).
Time Frame
week 0, week 12
Title
Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range
Description
Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL).
Time Frame
week 0, week 12
Title
Number of Hypoglycaemic Episodes
Description
Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.
Time Frame
weeks 0-12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes Diet and lifestyle changes or metformin monotherapy for at least three months HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive) Body Mass Index (BMI) less than or equal to 40 kg/m^2 Exclusion Criteria: Previous treatment with insulin (except for short term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator) Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including treatment in a clinical trial Treatment with any oral hypoglycaemic agents other than metformin in a period of 3 months prior to screening Current smoker or history of smoking within 6 months prior to screening Evidence of overt cardiovascular disease (documented coronary heart disease, class II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular disease) Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as judged by the Investigator Known retinopathy or maculopathy requiring acute treatment, as judged by the Investigator Known autonomic neuropathy, as judged by the Investigator Initiation or change (dose or treatment regimen) in concomitant blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23010561
Citation
Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.
Results Reference
result
PubMed Identifier
25212693
Citation
Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, Basu A. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res. 2014 Nov;11(6):419-30. doi: 10.1177/1479164114547358. Epub 2014 Sep 11.
Results Reference
result
PubMed Identifier
25504028
Citation
Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Erratum In: Diabetes Care. 2015 Aug;38(8):1622.
Results Reference
result
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs